Many medtech companies design large trials where a tiny, clinically meaningless response can be statistically significant. Dr. Holman advises entrepreneurs to instead run rigorous trials that prove genuine clinical value, arguing that credible data is the ultimate moat, even if it carries a higher risk of failure.

While smaller trials like KEYNOTE-905 can show dramatic results, they are subject to more statistical noise. Larger, thousand-patient studies like B15 and Niagara, with narrower confidence intervals, are considered closer to the true effect size and provide a more stable foundation for establishing the standard of care.

Instead of the high-risk approach of replacing a trial's control arm with digital twins, Unlearn.ai adds counterfactual data to every participant. This method increases a trial's statistical power, allowing for smaller control arms or a higher chance of success, while satisfying regulatory constraints for pivotal trials.

China’s efficiency in early-stage clinical trials is not a threat but a global asset. It allows for faster generation of proof-of-concept data, which helps de-risk programs for all companies before they undertake expensive, global trials for FDA approval.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.

Contrary to the common trend of diminishing efficacy in larger trials, Apogee's CEO highlights a historical pattern in atopic dermatitis where drug performance often improves from Phase 2 to Phase 3. This is attributed to larger study sizes reducing statistical noise and allowing for more refined site and patient selection.

China's ability to accelerate biotech development stems from faster patient recruitment for clinical trials. With a large, treatment-naive patient population willing to participate in studies, early-stage oncology trials can be completed in about half the time it takes in the US. This provides a significant strategic advantage for de-risking assets more quickly and cheaply.

China's biotech competitive advantage has shifted in two waves. The first involved leveraging its massive CRO ecosystem for efficient early discovery. The current wave is defined by unparalleled speed in clinical validation, enabled by a surge in patient participation and streamlined trial launch processes that accelerate proof-of-concept.

Unlike the U.S. system, which often requires separate ethics reviews for each trial location, China has adopted a "parallel ethics" model. If one site's ethics committee approves a trial, that approval extends to all other participating sites, drastically reducing administrative delays.